Hemopure for life-threatening anemia when blood transfusions aren’t an option
Part of Blood & lymphatic clinical trials.
This study offers HBOC-201 (Hemopure), a type of blood substitute made from bovine (beef) hemoglobin, to treat severe, life-threatening anemia. It’s meant for adults who have very low hemoglobin with serious signs of poor oxygen delivery, and who can’t (or don’t qualify) for standard blood transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your hemoglobin is 8 g/dL or lower, and you have active serious illness from low oxygen (for example, active bleeding, heart strain, confusion, kidney failure, or high lactic acid).
- You (or your legal health decision-maker) must be able and willing to sign informed consent.
- You cannot have a known severe allergy to beef products.
- You likely cannot join if you have uncontrolled high blood pressure, certain serious heart or kidney problems that aren’t controlled, too much fluid in the blood, or a mast cell condition called systemic mastocytosis.
- You likely cannot join if you are over 80 years old, or if doctors think you can receive regular blood transfusions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, HS-20106, to see if it can improve low red blood cell counts (anemia) for people with a certain type of bone marrow disorder called myelodysplastic syndromes (MDS), which is not high risk. It might be an option if you have not received certain prior treatments.
This trial tests whether giving blood in a personalized way, instead of a standard approach, is better for people on a heart-lung bypass machine (VA-ECMO) for heart-related shock. It may help find a safer blood transfusion strategy while you are critically ill.
This trial tests a blood management strategy to help people with anemia who are having coronary artery bypass surgery (CABG). If you qualify, you may receive a treatment to improve your blood counts before surgery, which could reduce the need for transfusions.
This study tests whether a personalized plan for when to give blood transfusions works better than the usual approach in people having heart surgery with a heart-lung machine. The goal is to find a safer and more effective way to manage transfusions during recovery.
This trial tests a special type of red blood cell transfusion that holds less oxygen. It may help people with sickle cell anemia who already get regular transfusions.
This trial looks at how to treat a severe, whole-body immune overreaction (“hemophagocytosis”) in adults who are critically ill. You might be considered if blood counts are low (white blood cells and platelets) and if you are already receiving a growth-factor medicine (rhG-CSF).
Hear when a new Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.